MIFH
INMB icon

Migdal Insurance & Financial Holdings’s INmune Bio INMB Stock Holding History

Migdal Insurance & Financial Holdings’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,003
Closed -$10K – 652
2021
Q4 		$10K Sell
1,003
-605
-38% -$8.96K ﹤0.01% 597
2021
Q3 		$31K Buy
+1,608
New +$31.1K ﹤0.01% 516

Other funds holding INMB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Migdal Insurance & Financial Holdings's INMB Position: Q1 2022 in Review

Migdal Insurance & Financial Holdings sold out of INmune Bio (INMB) in Q1 2022, closing a stake of 1,003 shares — an estimated $10K sold.

Migdal Insurance & Financial Holdings first reported a position in INMB in Q3 2021 and held it in 2 quarters. The position peaked at $31K in Q3 2021. 34 funds tracked by Wall St. Rank hold INMB as of Q1 2022.

  • Migdal Insurance & Financial Holdings reported no remaining INmune Bio position as of Q1 2022 after selling out during the quarter.
  • Migdal Insurance & Financial Holdings sold 1,003 INmune Bio shares in Q1 2022, an estimated $10K.
  • Migdal Insurance & Financial Holdings first reported a position in INmune Bio in Q3 2021 and held it in 2 quarters.
  • Migdal Insurance & Financial Holdings's INmune Bio position peaked at $31K in Q3 2021.
  • 34 funds tracked by Wall St. Rank held INmune Bio as of Q1 2022.

Based on Migdal Insurance & Financial Holdings's 13F filing for Q1 2022, filed 2 May 2022.